Nicolas Penel

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 2.8K citations · Full text

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

Nicolas Penel, Binh Bui, Jacques‐Olivier Bay et al. · Journal of Clinical Oncology · 2008 · 683 citations · Full text

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Isabelle Ray‐Coquard, Jean‐Yves Blay, Antoîne Italiano et al. · The Lancet Oncology · 2012 · 553 citations

Mdm2 Antagonist Rg7112, Medicine, Pharmacology +9

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín et al. · Journal of Thoracic Oncology · 2019 · 427 citations · Full text

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

Michele Maio, Paolo A. Ascierto, L. V. Manzyuk et al. · Annals of Oncology · 2022 · 404 citations · Full text